StemCell Therapy

Last week, the Cystic Fibrosis Foundation launched a new initiative called Path to a Cure. A press release called it an ambitious research agenda to deliver treatments for the underlying cause of the disease and a cure for every person with cystic fibrosis (CF).

It added: The Foundation is challenging potential collaborators to submit proposals that will accelerate the pace of progress in CF drug discovery and development and intends to allocate half a billion dollars to the effort through 2025.

News of the initiative comes nine days after an announcement by the U.S. Food and Drug Administration that it has approved the highly anticipated treatment Trikafta, a triple combination therapy of ivacaftor, tezacaftor, and the new elexacaftor (VX-445). Trikaftas clinical trial outcomes were remarkable and on par with the early clinical results from the highly effective Kalydeco several years ago, especially when compared with the outcomes of the not very robust but efficacious Orkambi and Symdeko.

The foundations strategic plan for the next five years is audacious, but I think its an honest pursuit. A year ago, I wrote about what a cure for CF might look like, and I discussed how the progressive and chronic nature of CF makes curing it a sort of nebulous concept.

In CF, the broken protein that is the underlying cause of the disease isnt the killer. The killers are the recurring infections, the inflammation, and the downstream effects of the broken cystic fibrosis transmembrane conductance regulator (CFTR) protein. Due to recurring infections, the lungs become damaged, and endemic bacteria become more resistant to traditional antibiotics.

For someone with moderate lung disease, fixing the underlying issue wont heal the scar tissue or reconstruct damaged airways. Most people with CF are pancreatic insufficient. Theoretically, an embryonic cure would prevent sustained damage to any part of the body. Once birth occurs, however, a cure would be too late to prevent even the slightest damage.

In the column from last year, I also wrote: Im not saying a cure is impossible or undesirable. Rather, there are multiple pillars to ultimately curing all the ills that deeply affect our lives. I think looking at a cure in this way is a reason to be hopeful. I added that I didnt believe this change of perspective about what a cure looks like should be a reason for discouragement.

What I like about the CF Foundations Path to a Cure is how theyre discussing what the different paths look like. Current therapies are modulators. At best, they repair CFTR protein, which is different than fixing or replacing it. This initiative also emphasizes the most important tenet of all CF therapies: It is intended to help everyone with CF. Complicated mutations will require different strategies.

A cure for cystic fibrosis is a complicated endeavor. CF is a particularly interesting genetic disease for many reasons, not least of which is that the pathway to curing it could be extrapolated to other diseases with genetic causes or predispositions. I do believe a cure is possible, though Im usually cautious to offer my commentary on the word cure.

Many subpopulations exist in the CF community. Thousands of people in the world have CF. A percentage of that population doesnt have access to the most basic CF treatments. Many people in the United States dont even have good access or care. Modulators arent approved for transplant patients.

Its not for nothing that the CF Foundation and the community itself must ask one important question: What does life look like for someone with feeble lung function that is cured of CF? If other treatment plans arent in place such as better transplant strategies utilizing stem cells, or using stem cells for lung regeneration a cure may not prolong life, but rather prolong the misery of end-stage disease.

Part of planning for the future is predicting the effects of that plan. But we must ask: How are we giving everyone with CF the chance to live well into their 70s and 80s? I think the important discoveries made along the way will be instrumental in learning if its possible to repair diseased lungs through regenerative medicine.

Path to a Cure is one of the most exciting research agendas weve seen. Im looking forward to the day when the CF Foundation announces that a cure has been found.

Follow along with my other writings on my humbly named site, http://www.trelarosa.com.

***

Note: Cystic Fibrosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of Cystic Fibrosis News Today, or its parent company, BioNews Services, and are intended to spark discussion about issues pertaining to cystic fibrosis.

Read this article:
What We Should Expect from the CF Foundation's 'Path to a Cure' - Cystic Fibrosis News Today

A huge leap could be made with bioprinting the 3D printing of tissue and organs thanks to an innovative idea which proposes to use aqueous architectures, or in other words, printing in a specially made fluid.

As Science magazine reports, human tissue and organs are very tricky to make using traditional 3D printing methods without putting support scaffolding in place and that scaffolding can later be very difficult (or indeed impossible) to remove.

So the idea as advanced by Chinese researchers is to move away from a solid support structure, and instead use liquid. Specifically, this would be a fluid matrix into which the liquid design for an organ could be injected, and the surrounding fluid then drained away after the organ has set.

This kind of approach has previously been attempted, except the fluid matrix hasnt proven stable enough, and the whole thing has simply collapsed. So instead these researchers from China have used hydrophilic (attracted to water molecules) liquid polymers which are capable of creating a stable membrane.

Using this method, the liquid structure is far more robust and is even capable of holding its shape for as long as 10 days. A further benefit is that during the process of pumping the ink into the fluid membrane, if mistakes are made, the nozzle can actually extract and rewrite the ink as needed.

The researchers believe that this advance in the field of bioprinting will help greatly with the production of complex tissue-like constructs including arteries and tracheae.

And this could have a major impact in terms of regenerative medicine, the scientists say, as well as producing in-vitro tissue models for studies and the likes of disease modeling, or potential applications like drug screening or development.

The researchers note that a commercially available 3D printer has been used in their early experiments thus far, albeit when printing multiple cells, a homemade microuidic nozzle head was employed instead.

See the original post here:
3D printing could have cracked the problem of making human organs - TechRadar

NEW YORK, Nov. 05, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the Company will hold a conference call to update shareholders on financial results for the third quarter ended September 30, 2019, and provide a corporate update, at 8:00 a.m., Eastern Standard Time, on Thursday, November 14, 2019.

BrainStorms President & CEO, Chaim Lebovits, will present a corporate update, after which, participant questions will be answered. Joining Mr. Lebovits to answer investment community questions will be Ralph Kern, MD, MHSc, Chief Operating Officer and Chief Medical Officer, and Preetam Shah, PhD, Chief Financial Officer.

Participants are encouraged to submit their questions prior to the call by sending them to: q@brainstorm-cell.com; Questions should be submitted by 5:00 p.m., Eastern Standard Time, Tuesday, November 12.

The investment community may participate in the conference call by dialing the following numbers:

Those interested in listening to the conference call live via the internet may do so by visiting the Investors & Media page of BrainStorms website at http://www.ir.brainstorm-cell.com and clicking on the conference call link.

A webcast replay of the conference call will be available for 30 days on the Investors & Media page of BrainStorms website:

About NurOwnNurOwn (autologous MSC-NTF) cells represent a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. BrainStorm has fully enrolled a Phase 3 pivotal trial of autologous MSC-NTF cells for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm also recently received U.S. FDA acceptance to initiate a Phase 2 open-label multicenter trial in progressive MS and enrollment began in March 2019.

About BrainStorm Cell Therapeutics Inc.BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (U.S. FDA) and the European Medicines Agency (EMA) in ALS. BrainStorm has fully enrolled a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six U.S. sites supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm also recently received U.S. FDA clearance to initiate a Phase 2 open-label multicenter trial in progressive Multiple Sclerosis. The Phase 2 study of autologous MSC-NTF cells in patients with progressive MS (NCT03799718) started enrollment in March 2019. For more information, visit the company's website at http://www.brainstorm-cell.com

Safe-Harbor Statement

Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could causeBrainStorm Cell Therapeutics Inc.'sactual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorms need to raise additional capital, BrainStorms ability to continue as a going concern, regulatory approval of BrainStorms NurOwn treatment candidate, the success of BrainStorms product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorms NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorms ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorms ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTS

Corporate:Uri YablonkaChief Business OfficerBrainStorm Cell Therapeutics Inc.Phone: 646-666-3188uri@brainstorm-cell.com

Media:Sean LeousWestwicke/ICR PRPhone: +1.646.677.1839sean.leous@icrinc.com

Excerpt from:
BrainStorm Cell Therapeutics to Announce Third Quarter Financial Results and Provide a Comprehensive Corporate Update - GlobeNewswire

IRVINE, Calif., Nov. 1, 2019 /PRNewswire/ --AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced that it will be presenting at the following regenerative medicine and investor conferences in November:

Society for the Immunotherapy of Cancer (SITC) Annual MeetingOral PresentationPresenter: Dr. Daniela Bota, MD, PhD, University of California, Irvine; AIVITA GBM Principal InvestigatorTitle: Phase II trial of therapeutic vaccine consisting of autologous dendritic cells loaded with autologous tumor cell antigens from self-renewing cancer cells in patients with newly diagnosed glioblastomaTime: November 6-10, 2019Location: Gaylord National Hotel & Convention Center, National Harbor, MD

The Regenerative Medicine Consortium of the Gulf Coast Consortia for Biomedical SciencesOral Presentation Presenter: Dr. Hans S. Keirstead, AIVITA Chairman and CEOTitle: Clinical and Commercial Application of Scaled Human Stem Cell DerivatesTime: November 8, 4:00 PM CTLocation: Bioscience Research Collaborative, Houston, TX

NYC Oncology Investor ConferenceOral Presentation Presenter: Dr. Hans S. Keirstead, AIVITA Chairman and CEO Title: AIVITA Corporate PresentationTime: November 12, 4:50 PM - 5:10 PMLocation: Rockefeller Center, New York, NY

Society for NeuroOncology Annual MeetingPoster PresentationTitle: Phase II trial of AV-GBM-1 (autologous dendritic cells loaded with autologous tumor associated antigens) as adjunctive therapy following primary surgery plus concurrent chemoradiation in patients with newly diagnosed glioblastoma.Time: November 20-24, 2019Location: JW Marriott Desert Ridge, Phoenix, AZ

About AIVITA Biomedical

AIVITA Biomedical is a privately held company engaged in the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. Founded in 2016 by pioneers in the stem cell industry, AIVITA Biomedical utilizes its expertise in stem cell growth and directed, high-purity differentiation to enable safe, efficient and economical manufacturing systems which support its therapeutic pipeline and commercial line of skin care products. All proceeds from the sale of AIVITA's skin care products support the treatment of women with ovarian cancer.

SOURCE AIVITA Biomedical, Inc.

Homepage

See original here:
AIVITA Biomedical to Present at Upcoming Regenerative Medicine, Oncology and Investor Conferences in November - PRNewswire

MCLEAN, Va.--(BUSINESS WIRE)--The Thought Leadership & Innovation Foundation (TLI) announces today plans to build on its existing Regenerative Medicine Program through a research collaboration with cellular therapy industry leader RenovaCare. As part of TLIs efforts to conduct vital research in regenerative medicine and chronic disease, this initiative aims to innovate methods for reducing complications from burn and diabetic wounds across large populations.

Our research base, collaborative institutions and long history of innovation align with RenovaCares commitment to breakthrough biomedical technologies, says Bill Oldham, founder and chairman of the Board, TLI. The patented RenovaCare SkinGun technology and its ability to ultra-gently spray stem cells could present a special opportunity for investigations and applications in a wide range of regenerative therapies. Working together, our overall goal is to improve the quality, efficiency and effectiveness of patient care by not only developing new treatment methods, but also by making thoughtful and systematic changes to healthcare and health systems.

TLIs Regenerative Medicine program seeks to adapt new strategies based upon sound scientific evidence, utilizing its infrastructure to support the continuation of scientific and medical work, as well as the development of grant-funded research and other initiatives.

Dr. Robin A. Robinson, who is a TLI Fellow, Vice President of Scientific Affairs, RenovaCare, and named one of the top 100 innovators in medicine by Medicine Maker in 2018, states, This exciting collaboration between RenovaCare and TLIs Regenerative Medicine Program is the first step toward the development of meaningful and quality therapeutic treatments that will benefit patients around the world.

About TLI Foundation:

TLI Foundation is a nonprofit foundation focused on driving innovative thinking and action on global issues relating to health, education and economic empowerment. The organization is committed to fostering transformative change and improving the health and well-being outcomes of communities around the world. Visit https://www.thoughtfoundation.org/

About RenovaCare:

RenovaCare, Inc. is a biotechnology company focused on developing first-of-their-kind autologous (self-donated) stem cell therapies for the regeneration of human organs. Initial products under development target the bodys largest organ, the skin. Investigative clinical use of their flagship technology has shown to be promising new alternatives for patients suffering from burns, and chronic and acute wounds. https://www.renovacareinc.com.

Originally posted here:
Thought Leadership & Innovation Foundation to Expand Its Regenerative Medicine Program Through New Collaboration with RenovaCare - Business Wire

A regenerative medicine company in Vancouver, British Columbia will begin Phase 1 studies in early 2020 for a treatment for nerve damage and degenerative diseases including Alzheimers disease.

NervGen Pharma wants to advance its proprietary therapeutic technology platform, currently in development for spinal cord injury and multiple sclerosis (MS), to generate new treatments for Alzheimer's disease.

The essence of our technology is that it takes the brakes off the bodys repair systems and allows the nervous system to repair itself, said Bill Radvak, the companys executive chairman and co-founder. You can think of it as the bodys nervous system has a housekeeping function that is constantly at work, fixing bad connections with new ones and tidying up redundant ones.

Digital

In a nutshell, the body produces a scar at sites of physical injury such as a spinal cord injury as well as sites of inflammatory damage from neurodegenerative diseases such as multiple sclerosis and Alzheimer's disease. The purpose of the scar is to encapsulate the site of the injury to prevent further damage but it ultimately inhibits the body's reparative mechanisms.

The co-inventor of NervGen's technology, Dr. Jerry Silver, Professor of Neurosciences at Case Western Reserve University's School of Medicine in Cleveland, Ohio, discovered that a component of these scars, a protein called CSPG, inhibits the body's natural ability to regrow and regenerate. NervGen's technology platform removes this inhibition and, via multiple endogenous repair mechanisms, unlocks the nervous system's ability to repair itself in a manner adapted to the site of injury and type of disease, Radvak said. Numerous repair mechanisms, including regeneration, plasticity and remyelination, have been observed in the various animal models such as stroke, spinal cord injury, multiple sclerosis, cardiac arrhythmia and peripheral nerve injury as reported in over a dozen peer reviewed papers.

In the injured state, the new nerves get stuck because the amount of CSPGs increase, and they bind to a receptor called PTPsigma, which is found on nerves, pinning them in place, Radvak explained.

NervGens core technology targets the protein tyrosine phosphatase sigma (PTP), a neural receptor that impedes nerve regeneration. Inhibition of this receptor has been shown to promote regeneration of damaged nerves and improvement of nerve function in animal models for various medical conditions, Radvak said.

NervGen has identified a series of receptor antagonistsdrugs that block or dampen biological response by binding to and blocking a receptor rather than activating it (think beta blockers)including its lead candidate, dubbed the NVG-291 compound, that they say is ready for clinical development. NervGen has been studying the compound to treat spinal cord injury. Now they want to identify other diseases for its use, including Alzheimers.

Our molecules unstick nerves and prevent new ones from getting stuck, he said. This same receptor, PTPsigma, is also found on myelin, or to be more scientifically correct, on OPCs [Oligodendrocyte progenitor cells] which develop into myelin. So, our treatment allows the myelin, which is damaged in MS, to repair itself.

Radvak said NervGen is hopeful the treatment will work in Alzheimers due to the nature of the disease itself. You also find the same problem in Alzheimers diseaseCSPGs are found in the plaques associated with the disease. We are hoping that our treatments can help the body remove the plaques and then allow new nerve connections to regrow. If our theory is correct, we hope that this could one day prevent and even reverse the disease and its terrible effects.

Alzheimer's disease is a progressive neurodegenerative disorder that destroys memory and cognitive functions. Scientists and others estimate 30 million people are affected by the disease globally including 5.8 million in the United States alone. Experts say, by 2025, the number of seniors with Alzheimer's disease could reach 7.1 million, and the prevalence of Alzheimer's disease could reach 13.8 million by 2050. The estimated cost in 2019 of caring for Americans with Alzheimer's disease and other dementias is $277 billion, a number that does not include unpaid caregiving. Of that amount, $186 billion is the cost to Medicare and Medicaid, and $60 billion is for out-of-pocket costs. Alzheimer's disease is currently ranked as the sixth leading cause of death in the United States, but recent estimates indicate that the disease may rank third, just behind heart disease and cancer, as a cause of death for seniors.

As Alzheimers research and development efforts have failed to produce new effective treatments in the last fifteen years, the medical community and pharmaceutical industry are seeking technologies with new approaches through new targets and pathways.

For example, earlier this year drug companies, Biogen and Eisai, announced they were scrapping two phase 3 trials of the investigational anti-amyloid agent aducanumab for Alzheimer's disease based on an interim futility analysis, Medscape reported this week, but in a surprising about-face, new data from the studies mean the drug is back on the table.

A statement released by the drug's manufacturers said a new analysis from the EMERGE trial shows that the drug actually met the primary endpoint of significant reduction in clinical decline, including cognition and function. In the ENGAGE trial, the cohort of patients who received a high dose of aducanumab support the findings from EMERGE, Medscape reported. They note that after consulting with the US Food and Drug Administration (FDA), regulatory approval for the drug is back on track and will be pursued.

"NervGen's platform technology introduces a truly novel approach to treating Alzheimer's disease," George Perry, PhD, said in a statement. Perry is the current editor-in-chief for the Journal of Alzheimer's Disease and professor of biology and Semmes Distinguished University Chair in neurobiology at the University of Texas at San Antonio.. "Work that began in the early 90s has confirmed the importance of the biological effect of proteoglycans in the central nervous system. In particular, the ability to shift microglia from the inflammatory phase to the phagocytic or housekeeping phase, as evidenced in both a spinal cord injury and multiple sclerosis model, is promising as it is the natural reparative process for removal of amyloid plaques. This demonstration of an immunomodulatory effect on the microglia will be of specific interest in the quest for a solution to Alzheimer's disease as the function of the microglia is one of the hot topics in this still evolving story."

Dr. Ernest Wong, NervGen's president and CEO said in a statement the Phase 1a study will be followed by a Phase 1b on subsets of both chronic and sub-acute spinal cord patients and a Phase 2 study on multiple sclerosis in 2021. Chondroitin sulfate proteoglycans (CSPGs} are intimately associated with senile plaques and our work with PTP knockout mice and other data with chondroitinase all suggest a pivotal role for PTP in AD, he said.

NervGen has taken this discovery into industrial development and is turning the platform into drugs to be developed, Radvak said. The NervGen programs are by far the most advancedwe are unaware of anyone else working with this approach. The company also has a number of patents which gives it exclusivity on this scientific approach. If we are successful and get the products to market, they would be a radically different treatment and first-in-class.

And though drug development takes time and several steps, Radvak said he is hopeful a treatment will be available soon. We are about to a big step by starting the first human trials, he said. The Company plans to submit an Investigational New Drug application with the U.S. Food and Drug Administration for NVG-291 with the intention of initiating a Phase 1 human clinical trial on healthy subjects in early 2020 and expansion of that trial in the second half of 2020 to include a cohort of spinal cord injury patients. In addition, NervGen intends to commence a Phase 2 multiple sclerosis clinical trial in early 2021.

This process takes a number of years for the product to get to market but drug development is like a relay race, he continued. Smaller companies develop drugs in the early steps and often hand over to Pharma for late stage development. At this handover, the company or product is sold to the Pharma which has increased capabilities to commercialize.

More here:
New Alzheimer Treatment Could Take The Brakes Off The Bodys Repair Systems Allowing It To Repair Itself - Forbes

Global Regenerative Medicine Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024 is the most important research for who looks for complete information about the Regenerative Medicine market. The report takes a critical look at the business regulatory framework, technological advances in associated industries, and strategic approaches. For market demand, size, trading, supply, competitors, and prices as well as global predominant vendors information, the report covers all information on the global and regional markets including old and future trends. The research study also explains upcoming industry supply, market demand, value, application, type, share, competition and its analysis of key players with industry forecast from 2019 to 2024.

The research report commits different factors affecting Regenerative Medicine industry such as past data and market trends, technological advancements, upcoming innovations, market risk factors, market restraints, and challenges in the industry. The study then describes the drivers and restraints for the market along with the impact they have on the demand over the forecast period. It also observes the latest trends and development plans, patterns, and policies observed in the global market.

DOWNLOAD FREE SAMPLE REPORT: https://marketandresearch.biz/sample-request/91858

This report includes the following top vendors in terms of company basic information, product category, sales (volume), revenue (Million USD), price and gross margin (%). They are: ABS Protection GmbH, Mammut, Clarus Corporation, Backcountry Access, Scott, Ortovox, ARVA, Osprey Packs, The North Face, Dakine, Mystery Ranch, Millet(Calida Group), Motorfist, Deuter,

On the basis of types, the market is primarily split into Mono Avalanche Airbags, Dual Avalanche Airbags

On the basis of applications, the market covers: Skiing, Climbing, Hiking, Others

On the basis of geography, the market covers: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

How Far Does The Scope of This Research Study Traverse?

ACCESS FULL REPORT: https://marketandresearch.biz/report/91858/global-regenerative-medicine-market-2019-by-manufacturers-regions-type-and-application-forecast-to-2024

Key Market Dynamics: The global Regenerative Medicine market research report forecasts the latest market trends, development methods, and research methodologies. Several factors that are directly affecting the market such as the strategic production and methods, development platforms, and the product model, as well as the minute change within the product profile, are included in the report.

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketandresearch.biz), who will ensure that you get a report that suits your needs.

Ron is a very well known face in the journalism world. He is the editor-in-chief of Top News Herald. He covers Business news for Top News Herald. He lives in Buffalo New York with his wife Melinda.

See more here:
Global Regenerative Medicine Market 2019 Worldwide Industry Analysis to 2024 - Top News Herald

POMPANO BEACH, FL, Oct. 29, 2019 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC/PK:BSEM) today announced Henry Van Vurst would be stepping down as the company's Chief Executive Officer and as Chairman of the Board of Directors, effective October 22, 2019. Henry is yielding the position to focus on sales and business development for the companys life sciences division. The BioStem Board of Directors has elected Jason Matuszewski, a co-founder and longtime member of the executive team, as the company's interim Chief Executive Officer and Chairman, effective October 22, 2019.

"The Board of Directors of BioStem Technologies has accepted Henrys decision to step down as CEO and Chairman to focus on business development and sales, said Jason Matuszewski. Matuszewski continued, as one of the founders of BioStem Technologies, I have a profound commitment to the success of our company and to ensure the continual focus of our vision and the execution of our strategy. I am fully invested in reassuming the role of CEO until such a time that this important responsibility can be transitioned to the right person following a systematic search that will allow us to maintain our focus on our important fourth quarter.

The company also announced the expansion of its leadership team with the addition of Ken Warrington, PhD as Senior Vice President of Operations. Dr. Warrington brings significant expertise in biopharmaceutical product development and cGMP production. Dr. Warrington will play a key role in the expansion of the laboratory production and development initatives as BioStem continues to accelerate its growth of the BioStem Life Sciences division.

About BioStem Technologies, Inc.(OTC PINK: BSEM):BioStem Technologies, Inc.is a global life sciences corporation, providing innovative technologies with a concentration in Regenerative Medicine. The companys mission is to discover, develop and produce the most effective Regenerative Medicine products in the world. The company is comprised of a diverse group of scientists, physicians, and entrepreneurs who collaborate to create innovative products. These technologies improve the Quality of Life for our patients and, as a result, drive shareholder value.

BioStem Life Sciences, Inc.A company focused on the development of the highest quality birth tissue products for multiple sectors of healthcare. BioStem Life Sciences offers a comprehensive portfolio of high quality brands that include Rheo, Vendaje and Vendaje Optic. BioStem Life Sciences also provides leading class contract manfuactuing services to GMP and GTP standards for companies looking to develop birth tissue products, from bench top to comericalization. For the latest news and information about BioStem Life Sciences and its brands, please visitwww.biostemlifesciences.com

Forward-Looking Statements: Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.

BioStem Technologies, Inc.Phone: 954-380-8342 Website: http://www.biostemtechnologies.com Email: info@biostemtech.comTwitter: @BiostemtechFacebook: BioStem Technologies

Investor Relations:Andrew Van Vurstinfo@biostemtech.com(954) 380-8342

The rest is here:
BIOSTEM TECHNOLOGIES, INC. ANNOUNCES CORPORATE UPDATE; RESIGNATION OF CHAIRMAN AND CEO, APPOINTMENT OF INTERIM CEO AND CHARIMAN; BOARD INITIATES...

BOTHELL, Wash., Oct. 31, 2019 /PRNewswire/ --BioLife Solutions, Inc. (BLFS), a leading developer and supplier of best-in-class bioproduction tools for cell and gene therapies, ("BioLife" or the "Company"), today announced that the Company's third quarter 2019 financial results will be released after market close on Tuesday, November 12, 2019, and that the Company will host a conference call and live webcast at 4:30 p.m. ET (1:30 p.m. PT) that afternoon. Management will provide an overview of the Company's financial results and a general business update.

Cell and gene therapy tools. (PRNewsfoto/BioLife Solutions, Inc.)

To access the webcast, log on to the Investor Relations page of the BioLife Solutions website at http://www.biolifesolutions.com/earnings. Alternatively, you may access the live conference call by dialing (844) 825-0512 (U.S. & Canada) or (315) 625-6880 (International) with the following Conference ID: 7207519. A webcast replay will be available approximately two hours after the call and will be archived on http://www.biolifesolutions.com for 90 days.

About BioLife Solutions

BioLife Solutions is a leading supplier of cell and gene therapy bioproduction tools. Our proprietary CryoStor freeze media and HypoThermosol shipping and storage media are highly valued in the regenerative medicine, biobanking and drug discovery markets. These biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. Our recently acquired ThawSTAR family of automated cell thawing products and evo cold chain management system reduce therapeutic and economic risk for cell and gene therapy developers by reducing the potential of administering a non-viable dose. For more information, please visit http://www.biolifesolutions.com and follow BioLife on Twitter.

View original content to download multimedia:http://www.prnewswire.com/news-releases/biolife-solutions-to-report-third-quarter-2019-financial-results-and-provide-business-update-on-november-12-2019-300949616.html

The rest is here:
BioLife Solutions to Report Third Quarter 2019 Financial Results and Provide Business Update on November 12, 2019 - Yahoo Finance

Cindi Bigelow, CEO of Bigelow Tea in Fairfield

Cindi Bigelow, CEO of Bigelow Tea in Fairfield

Photo: Dan Haar / Hearst Connecticut Media / Dan Haar / Hearst Connecticut Me

Cindi Bigelow, CEO of Bigelow Tea in Fairfield

Cindi Bigelow, CEO of Bigelow Tea in Fairfield

Innovation TED Talks coming to Fairfield University

FAIRFIELD Fairfield University will host a diverse line-up of speakers at a TEDx program on October 28.

TED stands for Technology, Entertainment, and Design topics that combined in 1984 to form the first TED Talk in Monterey, Calif.

Today, the idea has been expanded to sharing ideas worth spreading. TEDx, programs launched in 2009 to share TED-worthy ideas on a smaller scale.

Featured in the Fairfield U event at Wien Experimental Theatre of the Regina A. Quick Center for the Arts will be a current student, an alumna, an honorary degree recipient, and a faculty member, as well as individuals in health care, education, business, and technology.

Doors open at 2 p.m. and the event is free but registration is required. While TEDx audiences are capped at 100 to promote an intimate live experience, overflow attendees will be invited to watch the presentations via live-stream in the adjacent Kelley Theatre.

The theme for the event will be Innovation and Inspiration, in honor of the 25th anniversary of the university's School of Engineering.

The nine speakers include:

* Dr. Stephen F. Badylak, deputy director of the McGowan Institute for Regenerative Medicine.

* David C. Banks, president and CEO of The Eagle Academy Foundation, Inc.

* Cindi Bigelow, the third-generation president and CEO of Bigelow Tea, headquartered in Fairfield.

* Dr. Donna Coletti, scholar-in-residence at the Egan Schools Kanarek Center for Palliative Care.

* Lilliana Delmonico Class of 2020 and a bioengineering major in the School of Engineering and co-founder of the Biomedical Engineering Society at Fairfield University.

* Dr. T. Sloane Guy, professor of surgery and director of Minimally Invasive & Robotic Cardiac Surgery at Thomas Jefferson University Hospital.

* Aidan Kehoe, founder and CEO of Skout Cybersecurity.

* Dawne Ware, Class of 1989 and CEO of Ware Consulting LLC.

* Mark Unger, owner and director of Unger Global Companies, who wrote his book First Survivor, to honor those who helped him reject the diagnosis of zero chance of survival when his son was diagnosed with childhood cancer.

Excerpt from:
Innovation TED Talks coming to Fairfield University - CTPost

Most cancers kill because tumor cells spread beyond the primary site to invade other organs. Now, a USC study of brain-invading breast cancer cells circulating in the blood reveals they have a molecular signature indicating specific organ preferences.

The findings, which appear in Cancer Discovery, help explain how tumor cells in the blood target a particular organ and may enable the development of treatments to prevent the spread of cancers, known as metastasis.

In this study, Min Yu, assistant professor of stem cell and regenerative medicine at the Keck School of Medicine of USC, isolated breast cancer cells from the blood of breast cancer patients with metastatic tumors. Using a technique she developed previously, she expanded or grew the cells in the lab, creating a supply of material to work with.

Analyzing the tumor cells in animal models, Yus lab identified regulator genes and proteins within the cells that apparently directed the cancers spread to the brain. To test this concept, human tumor cells were injected into the bloodstream of animal models. As predicted, the cells migrated to the brain. Additional analysis of cells from one patients tumor predicted that the cells would later spread to the patients brain and they did.

Yu also discovered that a protein on the surface of brain-targeting tumor cells helps them to breach the blood-brain barrier and lodge in brain tissue, while another protein inside the cells shield them from the brains immune response, enabling them to grow there.

We can imagine someday using the information carried by circulating tumor cells to improve the detection, monitoring and treatment of the spreading cancers, Yu said. A future therapeutic goal is to develop drugs that get rid of circulating tumor cells or target those molecular signatures to prevent the spread of cancer.

Yu is a member of the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at USC, and her laboratory is located in the USC Norris Comprehensive Cancer Center.

In addition to Yu, other authors of the study are Remi Klotz, Amal Thomas, Teng Teng, Sung Min Han, Oihana Iriondo, Lin Li, Alan Wang, Negeen Izadian, Matthew MacKay, Byoung-San Moon, Kevin J. Liu, Sathish Kumar Ganesan, Grace Lee, Diane S. Kang, Michael F. Press, Wange Lu, Janice Lu, Bodour Salhia and Frank Attenello, all of the Keck School of Medicine; Sara Restrepo-Vassalli, James Hicks and Andrew D. Smith of USC Dornsife College of Letters, Arts and Sciences; and Charlotte S. Walmsley, Christopher Pinto, Dejan Juric and Aditya Bardia of Massachusetts General Hospital.

The study was supported by grants from the National Institutes of Health (DP2 CA206653) the Donald E. and Delia B. Baxter Foundation, the Stop Cancer Foundation, the Pew Charitable Trusts and the Alexander & Margaret Stewart Trust, the SC CTSI pilot grant (UL1TR001855 and UL1TR000130), a California Institute for Regenerative Medicine (CIRM) postdoctoral fellowship and a CIRM Bridges award (EDUC2-08381), and the National Cancer Institute (P30CA014089).

More stories about: Cancer, Research

See the original post:
New study reveals why breast cancer spreads to the brain - USC News

Phoenix,AZ(October 11, 2019) AxolotlBiologix, an innovative biotechnology leader in regenerative medicine,announced it has obtained HealthcareCommon Procedure Coding System (HCPCS) billing codes from the Centers forMedicare and Medicaid Services (CMS) for all its products effective October 1,2019.

Were thrilled that the CMS has made it easier forhealthcare providers to get reimbursed for treatments using Axolotl products,said Gary Lauterbach, CEO of AxolotlBiologix. Axolotls products are already part of the GSAs FederalSupply Schedule and areavailable through Indian Health Services and Veterans Affairs. Issuance of these HCPCS Q-Codes by CMS will help simplify thereimbursement process making it easier to utilize our regenerative products.

AxolotlsDualGraft and Axolotl Graft products have been assigned the code Q4210.Axolotls DualGraft is a bi-layered human amnion membrane patch that protectswounds while serving as a barrier to help encourage skin repair andreconstruction. DualGraft is a double-layered amniotic membrane convenientlypackaged as a dehydrated allograft, which can be stored at room temperature andapplied without special instruments in a clinical setting.

AxolotlAmbient and Axolotl Cryo products were assigned the code Q4215. AxolotlAmbient and Axolotl Cryo products are liquid allografts derived from theamniotic components of the placenta to promote regeneration and repair ofdamaged or degenerated tissue. The Ambient product is a liquid allograft that can be stored at an ambienttemperature (257C, 7713F).

For more information on Axolotl products visit http://www.axobio.com

About Axolotl Biologix:

Axolotl Biologix, Inc.is an innovative biotechnology leader in regenerative medicine throughresearch, technology and clinical application. Axolotl Biologix is expandingthe human bodys ability to regenerate by developing and manufacturingregenerative human cell and tissue medical technologies that are disruptingtraditional, more invasive, painful and expensive treatment protocols. For moreinformation, visit http://www.axobio.com

Media Contact:

JoshWeiss

10 to 1Public Relations

josh@10to1pr.com

480-789-0743

Read the original here:
Centers for Medicare and Medicaid Services Makes It Easier for Healthcare Providers to Choose Axolotl Biologix Products to Spur Wound and Tissue...

Antleron has created an R&D facility at their headquarters in Leuven, Belgium - a location known as an incubator for medical and life science innovation, including regenerative medicine, to support and validate customer projects in the field of 3D bioprinting. Antleron's 'living therapy factory' mergescells, biomaterials, biologics, bioreactors and 3D Systems printers to accelerate the engineering of living therapies. Using quality-by-design and artificial intelligence the Antleron multidisciplinary specialists translate these core technologies into pioneering workflows that turn cells into therapies.

The 3D Systems/Antleron relationship addresses solutions for medical device and advanced therapy medicinal product (ATMP) applications, incorporating a variety of innovative technologies that are of benefit to biomedical manufacturing process, beginning with 3D Systems' ProJet MJP 2500and Figure 43D printers and existing portfolio of 21 biocompatible, USP Class VI materials; 3D Sprintand 3DXpertsoftware, and post-processing equipment and processes. The goal is to establish a flexible, scalable Digital Factory approach, built on modular, closed parametric processes which include digital monitoring and quality control for risk mitigation. An example is to advance the way cells and tissues are grown to enable the transition from a static 2D to bioreactor-based 3D cell culture. This can lead to new ways to manufacture functionalized medical implants, vaccines, cell therapies, and living tissues.

According to Antleron CEO, Jan Schrooten, "The vision of Antleron is to sustainably bring living therapies into the clinic. 3D printing is key to this endeavor, and we are eager to collaborate with 3D Systems and its experts. I look forward to the pioneering solutions we'll be able to achieve to elevate the efficacy of bioprinting and extend its biomedical application reach."

"3D Systems is excited about working with Antleron as they explore bioprinting, and especially their capability to develop end-to-end solutions utilizing the 3D Systems' state of the art printing platforms and materials," said Chuck Hull, co-founder and chief technology officer, 3D Systems. "As we look to the future, bioprinting and regenerative medicine are large opportunities for 3D printing, and we look forward to expanding the role 3D Systems will play in these exciting fields."

At Formnext 2019 to be held November 19-22, 3D Systems (booth D03, hall 12.1) and Antleron will exhibit for the first time what is in store for next-generation medical applications with the ProJet MJP 2500 printer and VisiJet materials.

Forward-Looking StatementsCertain statements made in this release by or in reference to 3D Systems that are not statements of historical or current facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. In many cases, forward looking statements can be identified by terms such as "believes," "belief," "expects," "may," "will," "estimates," "intends," "anticipates" or "plans" or the negative of these terms or other comparable terminology. Forward-looking statements are based upon management's beliefs, assumptions and current expectations and may include comments as to the company's beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside the control of the company. The factors described under the headings "Forward-Looking Statements" and "Risk Factors" in 3D Systems' periodic filings with the U.S. Securities and Exchange Commission, as well as other factors, could cause actual results to differ materially from those reflected or predicted in forward-looking statements. Although management believes that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements are not, and should not be relied upon as a guarantee of future performance or results, nor will they necessarily prove to be accurate indications of the times at which such performance or results will be achieved. The forward-looking statements included are made only as the date of the statement. 3D Systems undertakes no obligation to update or review any forward-looking statements made by management or on its behalf, whether as a result of future developments, subsequent events or circumstances or otherwise.

About 3D Systems More than 30 years ago, 3D Systems brought the innovation of 3D printing to the manufacturing industry. Today, as the leading AM solutions company, it empowers manufacturers to create products and business models never before possible through transformed workflows. This is achieved with the Company's best-of-breed digital manufacturing ecosystem - comprised of plastic and metal 3D printers, print materials, on-demand manufacturing services and a portfolio of end-to-end manufacturing software. Each solution is powered by the expertise of the company's application engineers who collaborate with customers to transform manufacturing environments. 3D Systems' solutions address a variety of advanced applications for prototyping through production in markets such as aerospace, automotive, medical, dental and consumer goods. More information on the company is available at http://www.3dsystems.com.

About AntleronAntleron is a young R&D company on a mission to enable personalized manufacturing 4.0 in the domain of advanced therapies. The company's nimble team is revolutionizing medicine by merging the potential of cells, biomaterials, biologics, 3D printing and bioreactors to accelerate the engineering of living therapies - empowering patients with fully personalized, regenerative care. Antleron translates core technologies including additive manufacturing (AM), quality-by-design and artificial intelligence into pioneering workflows that turn cells into living therapies to eventually make organ manufacturing a reality. To support its mission, Antleron's business philosophy is to create sustainable ventures that bring living, personalized therapies from idea to patient through risk & reward sharing partnerships. From the company's headquarters in Belgium, Antleron operates at the cutting edge between life sciences and technology within Europe's leading biotech ecosystem. More information on the company is available at http://www.antleron.com.

SOURCE 3D Systems

http://www.3dsystems.com

See the rest here:
3D Systems and Antleron Collaborating to Accelerate 3D Printing Biomedical Breakthroughs - PRNewswire

According to a recent press release on Global Regenerative Medicines Market Outlook: Industry Analysis & Opportunity Evaluation 2018-2025 which delivers detailed overview of the global regenerative medicines market in terms of market segmentation by technology, source, application, end-users and region.

Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, trends and regulations & policies.

The Regenerative Medicines industry caters to the individuals with a long-term requirement to treat chronic oncogenic, immunogenic or infectious diseases. Research Nester released a report stating that the market is currently expanding and is expected to grow at a CAGR of 19.33% during the forecast period (2018-2027). By 2027, the global regenerative medicine market is predicted to reach USD 64.32 Billion.

Various funding programs initiated by the International Society for Stem Cell Research in the past as well as in the future are expected to attract large number of potential new players in the regenerative medicines market. Research Grants from organizations such as, Alexander von Humboldt Foundation Sponsorship Programmes, Alliance for Regenerative Rehabilitation and Training Center and Biotechnology, California Institute of Regenerative Medicine (CIRM) and Biological Sciences Research Council (BBSRC) are expected to create higher opportunities for regenerative medicines research and development.

Asia Pacific region is projected to witness enormous growth in forthcoming years. Country governments such as Japan and China across Asia-Pacific are drafting policies to advocate building new infrastructure (and research networks) to push towards a profitable commercialization of regenerative medicine products. Chinese Ministry of Science and Technology (MST),the State of Food and Drug Agency and the Ministry of Health have issued approximately 30 new rules and regulations to increase the development of regenerative medicines across the country. Further, in 2014 Pharmaceutical and Medical Device (PMD) Act and the Safety of Regenerative Medicine Act issued in Japan, new regulations to accelerate the approval process of regenerative medicine products. These initiatives across the countries of Asia-Pacific by the local governments are projected to drive the regenerative medicines market exponentially over the forthcoming years.

To Request a Report Sample for Research Scope CLICK HERE

The global regenerative medicines market is segmented on the basis of technology into gene therapies, cellular therapies, exosome therapeutics and tissue engineering wherein cellular therapies segment is further segmented into cellular immunotherapies, stem cell therapies, therapeutics utilizing, differentiated cell types and direct cell reprogramming.

Growing demand for organ transplantation in developed and developing countries and the commercialization of regenerative medicines are some of the key trends anticipated to supplement the growth of the global regenerative medicine market through the forecast period. Increased use of skin substitutes, grafts, bone matrix and other tissue engineered regenerative medicines are one of the prominent factor backing for the growth of the global regenerative medicine market over the forthcoming years.

The market is further segmented based on the source as autologous and allogeneic. Kite Pharma and Fosun Pharma created joint venture in China to commercialize autologous t-cell therapies to cure cancer in 2019. According to this agreement, Fosun Pharma will deliver the RMB equal of $20 million in financing to sustenance clinical development and engineering activities and kite will provide certain technical transfer facilities to the joint venture. Such ventures in the regenerative medicines market are boosting the autologous segmental growth around the globe.

Despite its innumerable benefits, Regenerative Medicines market is expected to have its own share of challenges and limitations such as the issues of high costs, requirement for highly skilled professionals, and stringent regulatory standards. These are some of the restraining factors that might affect the growth of the market over the forecast period.

This report also provides the existing competitive scenario of some of the key players of the global regenerative medicines market which includes company profiling of Smith & Nephew Plc., Sangamo, Integra LifeSciences Corporation, Novartis, Stryker Corporation and other prominent players. In order to expand the market presence, Regenerative Medicines companies are expanding their product line extensively. For an instance, Baxter International announced its participation in The Alliance for Regenerative Medicine (ARM) and the UC San Diego Sanford Stem Cell Clinical Center organized conference for its product upliftment and gaining greater insights into its research and development activities for regenerative medicines.

The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global Regenerative Medicines market that will help industry consultants, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.

To request a sample report for Technological Breakthroughs CLICK HERE

About Research Nester:

Research Nester is a one-stop service provider with a client base in more than 50 countries, leading in strategic market research and consulting with an unbiased and unparalleled approach towards helping global industrial players, conglomerates and executives for their future investment while avoiding forthcoming uncertainties. With an out-of-the-box mindset to produce statistical and analytical market research reports, we provide strategic consulting so that our clients can make wise business decisions with clarity while strategizing and planning for their forthcoming needs and succeed in achieving their future endeavors. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds.

Contact for more Info:

AJ Daniel

Email: sales@researchnester.com

U.S. Phone: +1 646 586 9123

U.K. Phone: +44 203 608 5919

Go here to see the original:
Regenerative Medicines - A More Effective and Result Oriented Way to treat chronic Diseases for Long Term Range - PharmiWeb.com

Report Scope: The scope of this report is broad and covers various type of product available in the stem cell and regenerative medicines market and potential application sectors across various industries.

New York, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Stem Cell and Regenerative Therapy Market" - https://www.reportlinker.com/p05791357/?utm_source=GNW The current report offers a detailed analysis of the stem cell and regenerative medicines market.

The report highlights the current and future market potential of stem cell and regenerative medicines and provides a detailed analysis of the competitive environment, recent development, merger and acquisition, drivers, restraints, and technology background in the market. The report also covers market projections through 2024.

The report details market shares of stem cell and regenerative medicines based on products, application, and geography.Based on product the market is segmented into therapeutic products, cell banking, tools and reagents.

The therapeutics products segments include cell therapy, tissue engineering and gene therapy. By application, the market is segmented into oncology, cardiovascular disorders, dermatology, orthopedic applications, central nervous system disorders, diabetes, others

The market is segmented by geography into the following regions: North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. The report presents detailed analyses of major countries such as the U.S., Canada, Mexico, Germany, the U.K. France, Japan, China and India. For market estimates, data is provided for 2018 as the base year, with forecasts for 2019 through 2024. Estimated values are based on product manufacturers total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.

Report Includes: - 28 data tables - An overview of global markets for stem cell and regenerative medicines - Analyses of global market trends, with data from 2018, estimates for 2019, and projections of compound annual growth rates (CAGRs) through 2024 - Details of historic background and description of embryonic and adult stem cells - Information on stem cell banking and stem cell research - A look at the growing research & development activities in regenerative medicine - Coverage of ethical issues in stem cell research & regulatory constraints on biopharmaceuticals - Comprehensive company profiles of key players in the market, including Aldagen Inc., Caladrius Biosciences Inc., Daiichi Sankyo Co. Ltd., Gamida Cell Ltd. and Novartis AG

Summary The global market for stem cell and regenerative medicines was valued at REDACTED billion in 2018.The market is expected to grow at a compound annual growth rate (CAGR) of REDACTED to reach approximately REDACTED billion by 2024.

Growth of the global market is attributed to the factors such as growingprevalence of cancer, technological advancement in product, growing adoption of novel therapeuticssuch as cell therapy, gene therapy in treatment of chronic diseases and increasing investment fromprivate players in cell-based therapies.

In the global market, North America held the highest market share in 2018.The Asia-Pacific region is anticipated to grow at the highest CAGR during the forecast period.

The growing government funding for regenerative medicines in research institutes along with the growing number of clinical trials based on cell-based therapy and investment in R&D activities is expected to supplement the growth of the stem cell and regenerative market in Asia-Pacific region during the forecast period.

Reasons for Doing This Study Global stem cell and regenerative medicines market comprises of various products for novel therapeutics that are adopted across various applications.New advancement and product launches have influenced the stem cell and regenerative medicines market and it is expected to grow in the near future.

The biopharmaceutical companies are investing significantly in cell-based therapeutics.The government organizations are funding research and development activities related to stem cell research.

These factors are impacting the stem cell and regenerative medicines market positively and augmenting the demand of stem cell and regenerative therapy among different application segments.The market is impacted through adoption of stem cell therapy.

The key players in the market are investing in development of innovative products. The stem cell therapy market is likely to grow during the forecast period owing to growing investment from private companies, increasing in regulatory approval of stem cell-based therapeutics for treatment of chronic diseases and growth in commercial applications of regenerative medicine.

Products based on stem cells do not yet form an established market, but unlike some other potential applications of bioscience, stem cell technology has already produced many significant products in important therapeutic areas. The potential scope of the stem cell market is now becoming clear, and it is appropriate to review the technology, see its current practical applications, evaluate the participating companies and look to its future.

The report provides the reader with a background on stem cell and regenerative therapy, analyzes the current factors influencing the market, provides decision-makers the tools that inform decisions about expansion and penetration in this market.Read the full report: https://www.reportlinker.com/p05791357/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

More:
Global Stem Cell and Regenerative Therapy Market - Yahoo Finance

NEW YORK, Oct. 21, 2019 /PRNewswire/ --

Regenerative Medicine Market Size, Share & Trends Analysis By Product (Primary Cell-based, Stem & Progenitor Cell-based), By Therapeutic Category (Dermatology, Oncology) And Segment Forecasts, 2019 - 2025

Read the full report: https://www.reportlinker.com/p05807250/?utm_source=PRN

The global regenerative medicine market size is expected to reach USD 5.60 billion by 2025, expanding at a CAGR of 11.6% over the forecast period. Regenerative medicines are expected to have a significant impact in healthcare to treat specific indications and chronic conditions. Therefore, high prevalence of cancer, neurodegenerative, orthopedic, and other aging-associated disorders coupled with increasing global geriatric population is driving the market growth. Moreover, rising prevalence of inheritable genetic diseases is anticipated to fuel the demand in the field of biotechnology field.

Market players are engaged in implementing novel protocols for the release of novel therapeutics. For instance, in July 2018, Convelo Therapeutics launched regenerative medicines for the treatment of various neurological diseases, such as multiple sclerosis.Agreements models initiated by the companies coupled with commercialization in emerging countries fuels the growth. For instance, in March 2018, Hitachi Chemical signed an agreement with the Daiichi Sankyo and SanBio Group to conduct clinical manufacturing of regenerative medicines developed by respective companies for Japanese and U.S. markets.

Regenerative medicine is anticipated to witness great attention in healthcare sector due to its wide range of applications and significant advancements tissue engineering, stem cells, gene therapy, drug discovery, and nanotechnology. For example, 3D printing is preferred over scaffold with stem cells to restore structure and functional characteristics of biological specimens.

Dermatology is estimated to hold the largest market share in terms of revenue in 2018, owing to the availability of various products and their application in simple and chronic wound healing. Oncology therapeutic category on the other hand, is projected to expand at the fastest CAGR during the forecast period owing to the presence of strong pipeline of regenerative medicines for cancer treatment.

North America held the largest regenerative medicine market share in terms of revenue in 2018 and is projected to continue its dominance in near future. A significant number of universities and research organizations investigating various stem cell-based approaches for regenerative apposition in U.S. is anticipated to propel the growth.

Further key findings from the report suggest: Therapeutics emerged dominant among product segments in 2018 due to high usage of primary cell-based therapies along with advances in stem cell and progenitor cell therapies Implementation of primary cell-based therapies in dermatological, musculoskeletal, and dental application results in highest share of this segment Stem cell and progenitor cell-based therapies are anticipated to witness rapid growth due to high investments in stem cell research and increasing number of stem cell banks With rise in R&D and clinical trials, key players are offering consulting services leading to lucrative growth of the services segment Asia Pacific is projected to witness the fastest CAGR during the forecast period due to rapid adoption of cell-based approaches in healthcare and emergence of key players Key players operating in the regenerative medicine market including AstraZeneca; F Hoffmann-La Roche Ltd.; Pfizer Inc.; Merck & Co., Inc.; Integra LifeSciences Corporation; and Eli Lilly and Company

Read the full report: https://www.reportlinker.com/p05807250/?utm_source=PRN

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________Contact Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

Read more:
The global regenerative medicine market size is expected to reach USD 5.60 billion by 2025, expanding at a CAGR of 11.6% over the forecast period -...

MIAMI - October 24, 2019 - ( Newswire.com )

The AASCP has recently created guidelines thatare current safety recommendations given to physicians who are using biologics in their medical practice. A highly anticipated and sought after Safety StandardsPanel session, hosted by AASCP on Nov. 2, 2019, will be moderated by The Alliance for Cell Therapy Now,with President Ms. Janet Marchbrody.The sessions normally are closed to the public but this particular SafetyStandard Panel discussion will be open to the public, covering the growing safety concerns of the industry.

Alliance for Cell Therapy Now is a coalition of organizations representing patients, health care providers and the academic and scientific community, who are working together to advance safe and effective regenerative cell therapies. The mission is to advance the development, manufacturing and delivery of safe and effective regenerative cell therapies through policy development, consensus and advocacy. Alliance for Cell Therapy Now is bringing together experts and stakeholders to gain consensus on and advocate for policies that will advance the science and the field, including those focused on promoting clinical research, assuring the adoption of consensus standards to promote safety and quality, building capacity and expertise within the workforce, and establishing a national outcomes database to advance the science, promote improvements in quality and safety, and inform regulatory, paymentand patient decision-making.

Alliance for Cell Therapy Now is guided by an Advisory Board comprised of leaders in the scientific, academicand patient communities; Ms. Janet M. Marchibroda President, Alliance for Cell Therapy Now Fellow, Bipartisan Policy Center Senior Vice President, Health Policy, Bockorny Group, has agreed to join theAASCP as a moderator for their SafetyPanelat The Hyatt Regency in Miami. This particular coveted safetypanel session will be open to the public and broadcast live on YouTube at 3:00 p.m. on Nov. 2, 2019.

According to AASCP, if you are using biologics in your practice, whether you are using SVF, PRP, bone marrow, UCB, amniotic products,exosomes,xenografts, or peptides, there are key considerations to take into account to achieve the best safety for your patients. The AASCP also recommends communication with the Chief Scientific Officer from the laboratory you work with.AASCP advises that just talking to a sales agent is not sufficient enough when determining the quality of products for your patients. Sales agents typically do not have a medical or scientific background.

The spokesman for the AASCP, Dr. AJFarshchian,said earlier: The American Academy of Stem Cell Physicians is a group of physicians, scientists and researchers who collectively represent the most authoritativenon-federal group advocating for guidelines and education on stem cell therapy and regenerative medicine. AASCP members are experts within all fields of stem cell therapy from: SVF, BM, UCB, Exosomes, Peptides, Xenografts, Allografts and Amniotic Fluids and are considered the most experienced leaders for proper advocacy in the field. The AASCP is involved directly with other authorities within the field and seeks only to bring knowledge and awareness for the ever growing regenerative medicine industry.My hope is that the SafetyPanel discussion on Nov.2, 2019, is to help get rid of the bad actors that are damaging the field for everyone.

AASCP is hosting their medical conference in Miami on Nov. 1-3 , 2019. Sessions are normally closed to the public and, therefore, require registration. The conference is taking place at the downtown MiamiHyatt Regency, located at 400 SE 2nd Ave, Miami, FL 33131.Becauseof limited seating, we encourage everyone to please RSVP ataascp.net andto register.

The American Academy of Stem Cell Physicians (AASCP) is an organization created to advance research and the development of therapeutics in regenerative medicine, including diagnosis, treatmentand prevention of disease related to or occurring within the human body. Secondarily, the AASCP aims to serve as an educational resource for physicians, scientistsand the public in diseases that can be caused by physiological dysfunction that areameliorableto medical treatment.

For further information, please contact Marie Barbaat AASCP 305-891-4686 and you can also visit us at http://www.aascp.net.

Related Links AASCP Safety guidelinesAASCP website / registration

Press Release Service by Newswire.com

Original Source: American Academy of Stem Cell Physicians Announced Today That Their Safety Panel Session is Open and Free to the Public

Follow this link:
American Academy of Stem Cell Physicians Announced Today That Their Safety Panel Session is Open and Free to the Public - Valdosta Daily Times

Nerve Repair And Regeneration Market Size, Share & Trends Analysis Report By Surgery (Nerve Grafting, Neurorrhaphy), By Product (Biomaterials Neurostimulation & Neuromodulation Device), And Segment Forecasts, 2019 - 2026

New York, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Nerve Repair And Regeneration Market Size, Share & Trends Analysis Report By Surgery, By Product And Segment Forecasts, 2019 - 2026" - https://www.reportlinker.com/p05807210/?utm_source=GNW

The global nerve repair and regeneration market size is expected to reach USD 17.8 billion by 2026 registering a CAGR of 10.7%. Demand for neurological disorder therapies owing to increasing incidence and rising awareness about the same will drive the market. Moreover, government funding and reimbursement policies and uninterrupted technological advances are also projected to help boost the market growth.

In January 2016, the EU Horizon 2020 program funded a research project Autostem, launched by the NUI Galways Regenerative Medicine Institute (REMEDI), costing about USD 6.73 million. This project was to develop a robotic stem cell production factory, having an edge over the old traditional techniques. This technique offers prospects of new therapies for a range of diseases, such as cancers, diabetes, and arthritis. Increased R&D and investments by key companies in emerging countries are also driving the market growth. In July 2018, the Stem Cells Australia (SCA) received USD 3 million for stem cell research from the Medical Research Future Fund (MRFF).

In addition, government and private funded organizations are conducting clinical trials to develop a safe and effective therapy for different neurological disorders, such as Stem Cells in Umbilical Blood Infusion for Cerebral Palsy (Phase II) and usage of Polyethylene glycol (PEG) drug (Phase I) to promote axonal fusion technique to repair peripheral nerve injuries in humans.

Furthermore, in October 2017, Stryker Corporation acquired VEXIM, a France-based medical device company.VEXIMs portfolio is complementary to Strykers Interventional Spine (IVS) portfolio.

With this acquisition, Stryker will strengthen its distribution channels in Eastern Europe, Middle East, Asia, and Latin America. In January 2018, Boston Scientific Corporation received U.S. FDA approval for the first and only Spectra WaveWriter spinal cord stimulator system. This system is used for paresthesia-based therapy.

Further key findings from the study suggest: In 2018, neuromodulation and neurostimulation devices segment led the market due to increased cases of Central Nervous System (CNS) disorders and awareness about mental disorders and available treatments Biomaterials is anticipated to expand at the fastest CAGR during the forecast period due to technological advancements and development of biodegradable polymers that can help enhance spinal stabilization, healing of fractures, and reduce hospitalization North America led the market in 2018 owing to technological advancements and advent of new devices. Government initiatives and funding and increased cases of injured CNS, such as injuries to the spinal cord and brain, were some of the major reasons responsible for the regions growth Asia Pacific is expected to be the fastest-growing market during the forecast period. Growing geriatric population, technological advancements, and many unmet medical needs are some of the factors driving the regions growth In February 2016, Indian scientists working for Revita Life Sciences were approved to conduct clinical trials in 20 clinically dead patients to bring specific parts of their CNS back to life Combination of therapies including cocktail of peptides, nerve stimulation techniques, injecting the brain with stem cells and other techniques that were successful in bringing patients out of coma were to be used Existing medical devices were combined with regenerative biological medicines with an objective to achieve such a complex initiative Some of the key companies include Boston Scientific, Inc.; Stryker Corporation; St. Jude Medical, Inc.; Medtronic plc.; Baxter International, Inc.; AxoGen, Inc.; Polyganics B.V.; Integra; Cyberonics, Inc.; and Lifesciences CorporationRead the full report: https://www.reportlinker.com/p05807210/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

Follow this link:
The global nerve repair and regeneration market size is expected to reach USD 17.8 billion by 2026 registering a CAGR of 10.7% - Yahoo Finance

NEW YORK, Oct. 24, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced, Chaim Lebovits, President and CEO, will serve as a Keynote Speaker at Cell Series UK.Cell Series UK, will be held October 29-30, 2019, at London Novotel West, London, UK. The Conference, organized by Oxford Global, is one of the foremost events in Europe focused on regenerative medicine and cellular innovation.

Ralph Kern MD, MHSc, Chief Operating and Chief Medical Officer of Brainstorm, who will also participate at Cell Series UK stated, We are very pleased to have Chaim Lebovits presenting at this prestigious conference where global leaders in stem cell and regenerative medicine will have the opportunity to learn more about NurOwn and the critical research being conducted by the Company. Mr. Lebovits Keynote Address, Stem Cell Therapeutic Approaches For ALS, will be presented to leading members of the scientific and business community including potential partners and investors.

About NurOwnNurOwn (autologous MSC-NTF cells) represent a promising investigational approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. NurOwn is currently being evaluated in a Phase 3 ALS randomized placebo-controlled trial and in a Phase 2 open-label multicenter trial in Progressive MS.

AboutBrainStorm Cell Therapeutics Inc. BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn Cellular Therapeutic Technology Platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (U.S. FDA) and the European Medicines Agency (EMA) in ALS. BrainStorm has fully enrolled the Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six sites in the U.S., supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a BLA filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm received U.S. FDA clearance to initiate a Phase 2 open-label multi-center trial of repeat intrathecal dosing of MSC-NTF cells in Progressive Multiple Sclerosis (NCT03799718) in December 2018 and has been enrolling clinical trial participants since March 2019. For more information, visit the company's website.

Safe-Harbor Statements Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could causeBrainStorm Cell Therapeutics Inc.'sactual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorms need to raise additional capital, BrainStorms ability to continue as a going concern, regulatory approval of BrainStorms NurOwn treatment candidate, the success of BrainStorms product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorms NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorms ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorms ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTS

Corporate:Uri YablonkaChief Business OfficerBrainStorm Cell Therapeutics Inc.Phone: 646-666-3188uri@brainstorm-cell.com

Media:Sean LeousWestwicke/ICR PR Phone: +1.646.677.1839sean.leous@icrinc.com

See the original post here:
BrainStorm Cell Therapeutics' President and CEO to be Featured as Keynote Speaker at Cell Series UK 2019 - GlobeNewswire

The build-out is estimated at $9.5M.

United Therapeutics received a building permit Tuesday for a $9.5M build-out of its cell therapy facility on the second floor of Mayo Clinics Discovery and Innovation Building.

The 21,843-square-foot space will house an automated stem cell manufacturing site, which is one of the first of its kind in the country. The Whiting-Turner Contracting Co. is the project contractor.

The technology, approved by the FDA in 2018, allows the Mayo Clinic Center for Regenerative Medicine to produce cells from the bone marrow of a stem cell donor in large enough quantities to be used as treatments in clinical trials. It allows for the treatment of multiple patients at the same time.

Construction began in 2017 on the $32.4M building at 14221 Kendall Hench Drive. It held a grand opening in August.

The first floor houses three ex-vivo lung perfusion surgical suites used for lung restoration, another form of regenerative medicine. It turns donor lungs, which previously would have previously been unusable, into viable transplant organs. United Therapeutics also collaborates with Mayo Clinic on lung restoration.

The third floor houses the Life Sciences Incubator for biotech entrepreneurs, which offers coworking space, wet labs, business resources, networking and entrepreneurial training.

Read more:
United Therapeutics Receives Permit For Cell Therapy Facility Build-Out At Mayo - Pharmaceutical Online